(SQNM) - shortSequenom said employee mishandling of R&D test data and results has forced it to delay the launch of a Down syndrome test.-------Sign up and get instant entry alerts for the Free...
Sequenom, Inc. (NASDAQ: SQNM), a leading provider of genetic
analysis solutions, today announced that it will release 2008 second
quarter financial results after market...
Sequenom, Inc. (NASDAQ:SQNM), a leading provider of fine mapping genotyping, methylation and gene expression analysis solutions, today announced the commercial launch of its...
Company Acquires Rights to DNA and RNA Readout Technology That Holds Potential for Cost-Effective and Ultra Rapid Human Genome Sequencing
Sequenom, Inc. (NASDAQ:SQNM) today announced...
Sequenom, Inc. (NASDAQ:SQNM), a leading provider of fine mapping genotyping, methylation and gene expression analysis solutions, today announced that research conducted under the Cancer...
SAN DIEGO--(BUSINESS WIRE)--Sequenom, Inc. (NASDAQ: SQNM) today announced that its MassARRAY® technology and iPLEX™ assay were used by leading scientists from international...
SAN DIEGO--(BUSINESS WIRE)--Sequenom, Inc. (Nasdaq:SQNM) today reported financial results for the three months and year ended December 31, 2006. Revenues for the fourth quarter...